Medazepam and the driving ability of anxious patients

Area of Science:

• Psychopharmacology
• Clinical Psychology
• Human Factors Research

Background:

• Anxiety disorders are prevalent in hospital settings.
• Benzodiazepines are commonly prescribed for anxiety.
• Medazepam is a benzodiazepine anxiolytic with limited research on its efficacy and side effects in specific patient populations.

Purpose of the Study:

• To evaluate the efficacy of Medazepam in reducing anxiety in hospital patients.
• To assess the impact of Medazepam on cognitive function, driving performance, and physiological parameters.
• To investigate potential dose-dependent effects and side effects of Medazepam.

Main Methods:

• A double-blind, placebo-controlled, crossover trial was conducted.
• Fourteen anxious hospital patients participated.
• Anxiety was assessed using clinical ratings and the Middlesex Health Questionnaire (M.H.Q.).
• Driving performance was evaluated using simulator and real-world driving tests.
• Depression scores, pulse, and blood pressure were monitored.

Main Results:

• Medazepam was not more effective than placebo in relieving anxiety.
• The mean daily dosage of Medazepam was 16.5 mg.
• Medazepam significantly increased depression scores on the M.H.Q. scale.
• No adverse effects on braking and driving simulator tests were observed.
• Patients taking Medazepam made more technical, but not dangerous, errors in real driving conditions.
• Pulse and blood pressure remained unaffected.

Conclusions:

• The relatively low dosage of Medazepam may explain its lack of anxiolytic efficacy in chronically anxious hospital patients.
• Medazepam may have a negative impact on mood, increasing depression.
• While not impairing basic driving simulator performance, Medazepam can affect real-world driving accuracy.
• Further research with higher dosages or in different patient groups may be warranted.